Oramed CEO Nadav Kidron spoke to AFP about the advantages of Oravax Medical’s oral Covid-19 vaccine: no needles, no medical professionals required to administer it, potentially delivered directly to people’s homes. Oral vaccines are particularly attractive for the developing world, because they reduce the logistical burden of immunization campaigns. Read more here.
Israel is about to become the first country in the world to test the oral Covid-19 vaccine developed by Oramed Pharmaceuticals, the company’s CEO Nadav Kidron told The Jerusalem Post. Oramed’s subsidiary, Oravax Medical, is gearing up to commence clinical trials of its oral vaccine at Sourasky Medical Center in Tel Aviv. Read more here.
Forbes discusses how Israel is gearing up to host the first clinical trials of Oravax’s oral Covid-19 vaccine, which could help boost access to vaccines around the world. The vaccine should be “much more resistant to Covid-19 variants,” Kidron said, as it trains the immune system against three viral proteins. Read more here.